The purpose of this study was to determine whether 2,3-MDMA posed a potential problem for the proper identification of 3,4-MDMA or could be confused for the latter using routine analytical procedures employed in drug testing laboratories.
Following liquid-liquid extraction and derivatization with heptafluorobutyric anhydride, 2,3-and 3,4-MDMA, along with 3,4-MDA, were analyzed using an HP-1 capillary GC column (12-m, 0.20-ram i.d., 0.33-pro film thickness).
The GC conditions included the set injector and interface temperatures of 270~ and the oven temperature was programmed from 80~ for 1.00 min to 280~ at 20~ This procedure is routinely used for the analysis of MDA, MDMA, and methylenedioxyethylamphetamine from biological samples in our laboratory using a Hewlett-Packard 6890 GC coupled with an HP 5973 MS using a 7683 autoinjector. In the current experiments, full-scan mass spectra were obtained by scanning from m/z 50-500. All prominent ions in the MDMA spectra were monitored using the selected-ion monitoring mode (rn/z 135, 162, 210, 254, and 389), and their ratios were determined and compared using data from six replicate injections for each derivatized compound.
Each of these compounds were well separated chromatographically. Ratios at m/z 210 were closer but still showed a statistically significant difference (p < 0.00000002); however, the review of the data showed that it is possible for the 2,3-MDMA to produce an ion ratio that would fall within the lower limit of the + 20% range of the 254:210 ratio of 3,4-MDMA. The 254:389 ion ratio was not significantly different (p = 0.098) between the two compounds (Table I) . It is clear from the data in this report that the derivatized 2,3-MDMA is easily separated from its more common regioisomer 3,4-MDMA under commonly used derivatization and chromatographic conditions. Even though the compounds share the same prominent ions, chromatographic resolution eliminates any potential interference. 
